Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NCK1 | P16333 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252937 | 0.92 | CYP1A2 (0.52) | CYP1A2CYP2A6TDP1CCR1CCR5 | |
| SCHEMBL1412043 | 0.78 | CYP2A6 (0.52) | CYP1A2CYP2A6TDP1KDM4ELMNA | |
| SCHEMBL17193074 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL1204605 | 0.76 | CYP2A6 (0.50) | CYP1A2CYP2A6TDP1KDM4ELMNA | |
| SCHEMBL31556379 | 0.75 | CYP2A6 (0.46) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| SCHEMBL16637560 | 0.75 | CYP2A6 (0.46) | CYP2A6LMNAMAPT | |
| SCHEMBL2775348 | 0.75 | CYP1A2 (0.46) | CYP1A2CYP2A6BACE1 | |
| SCHEMBL1536308 | 0.75 | CYP2A6 (0.46) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E | |
| SCHEMBL31228277 | 0.75 | CYP1A2 (0.46) | CYP1A2CYP2A6BACE1 | |
| SCHEMBL15304446 | 0.75 | CYP2A6 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| EP-4257625-A1 | HCFO-CONTAINING ISOCYANATE-REACTIVE COMPOSITIONS, RELATED FOAM-FORMING COMPOSITIONS AND FOAMS | Covestro LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230303757-A1 | HCFO-CONTAINING ISOCYANATE-REACTIVE COMPOSITIONS, RELATED FOAM-FORMING COMPOSITIONS AND FOAMS | COVESTRO LLC | 2023-09-28 | — | — | US | disclosed |
| US-7718374-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | ELITECH HOLDING B.V. (NL) | 2010-05-18 | — | — | US | disclosed |
| US-20090087922-A1 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| EP-1670928-A4 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7348146-B2 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | EPOCH BIOSCIENCES, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1670928-A2 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | Epoch Biosciences, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050118623-A1 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | EPOCH BIOSCIENCES, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005035545-A2 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES | EPOCH BIOSCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | disclosed |
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | disclosed |
| EP-1109809-A1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | Cerebrus Pharmaceuticals Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000012502-A1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | CYP1A2 853/4885CYP2A6 1350/4885TDP1 195/4885 |
| US-20050118623-A1 | Single nucleotide polymorphism analysis of highly polymorphic target sequences | TSG101, CD74, HLA-DRB1 | CYP1A2 4395/4885CYP2A6 2886/4885TDP1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.